You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb1961890 |
---|---|
Category | Proteins |
Description | SLAMF3 (CD229) is a type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family. Mature human SLAMF3 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig-like V-set and two Ig-like truncated C2-set domains. The ECD of human SLAMF3 shares 57% - 59% aa sequence identity with mouse and rat SLAMF3. Within the first two Ig-like domains that are common to all SLAM proteins, human SLAMF3 shares 24% - 39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. It is expressed on T and B cells, thymocytes, and more weakly on NK cells. It may participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A. SLAMF3 may be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. It also disable autoantibody responses and inhibit IFN-gamma secretion by CD4+ T-cells and negatively regulate the size of thymic innate CD8+ T-cells and the development of invariant natural killer T (iNKT) cells. |
Tag | C-6xHis |
Purity | 98.00% |
MW | 75 KDa (reducing condition) |
UniProt ID | Q9HBG7 |
Protein Sequence | Lys48-Lys454 |
Expression System | HEK293 Cells |
Biological Origin | Human |
Biological Activity | SLAMF3 (CD229) is a type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family. Mature human SLAMF3 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig-like V-set and two Ig-like truncated C2-set domains. The ECD of human SLAMF3 shares 57% - 59% aa sequence identity with mouse and rat SLAMF3. Within the first two Ig-like domains that are common to all SLAM proteins, human SLAMF3 shares 24% - 39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. It is expressed on T and B cells, thymocytes, and more weakly on NK cells. It may participate in adhesion reactions between T lymphocytes and accessory cells by homophilic interaction. Promotes T-cell differentiation into a helper T-cell Th17 phenotype leading to increased IL-17 secretion; the costimulatory activity requires SH2D1A. SLAMF3 may be involved in the maintenance of peripheral cell tolerance by serving as a negative regulator of the immune response. It also disable autoantibody responses and inhibit IFN-gamma secretion by CD4+ T-cells and negatively regulate the size of thymic innate CD8+ T-cells and the development of invariant natural killer T (iNKT) cells. |
Expression Region | Lys48-Lys454 |
Storage | -20°C |
Note | For research use only |
Application notes | Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Expiration Date | 6 months from date of receipt. |
The purity of the protein is greater than 90% as determined by SDS-PAGE and Coomassie blue staining. | |
The protein has a predicted molecular mass of 45.6 kDa after removal of the signal peptide.The apparent molecular mass of SLAMF3-His is approximately 55-70 kDa due to glycosylation. | |
Mammalian |
98.00% | |
65-75 KDa (reducing condition) |
> 95% by SDS-PAGE. | |
Recombinant Human SLAMF3 Protein is produced by Mammalian expression system. The target protein is expressed with sequence (Lys48-Lys454) of human SLAMF3 (Accession #Q9HBG7) fused with a 6xHis Tag at the C- terminus. |